The company has designed, synthesized, patented, and tested in preclinical cancer models multiple retinoic acid nuclear receptor gamma agonists. These compounds promote development of tumor infiltrating T-lymphocytes and have anti-cancer activities through stimulation of the immune system, rather than through direct cytotoxic effects on tumor cells. IRX5010, the lead compound of the series, is effective in animal models of non-small cell lung cancer, triple or negative breast cancer, HER2+ breast cancer, colon cancer, and prostate cancer. The company is planning to conduct clinical trials in cancer patients with IRX5010.
Immuno-oncology Autoimmune Therapeutics Neurotherapeutics